Division: Pharmacy Policy	Subject: State of Florida's Agency for Health Care Administration's Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 6, 2022

Diacomit™ (stiripentol)

LENGTH OF AUTHORIZATION: Up to one year

REVIEW CRITERIA:

- Patient must be ≥ 2 years of age.
- Patient must have a diagnosis of Dravet syndrome (DS).
- Prescribed by or in consultation with a neurologist or epileptologist.
- Medication will be used in adjunct to clobazam.
- Baseline serum hematologic testing has been completed.

CONTINUATION OF THERAPY

- Patient met initial review criteria; **AND**
- Documentation of improved clinical response; **AND**
- Patient has not experienced any treatment-restricting adverse effects; **AND**
- Dosing is appropriate as per labeling or is supported by compendia; **AND**
- Hematologic testing has been completed every 6 months.

DOSING AND ADMINISTRATION:

- Refer to product labeling at https://www.accessdata.fda.gov/scripts/cder/daf/
- Available as:
  - 250 mg and 500 mg capsule
  - 250 mg and 500 mg powder for oral suspension.